Takeda Initiates Phase II Clinical Trials of Quadrivalent Vaccine

Japan's Takeda Pharmaceutical has launched its phase II clinical trials of quadrivalent vaccine TAK-361S.

Takeda Pharmaceutical has initiated phase II clinical trials of quadrivalent vaccine TAK-361S in Japan.

TAK-361S is a combination of the combined diphtheria, tetanus, and acellular pertussis vaccine (trivalent vaccine) that has already been marketed by Takeda, and the inactivated poliovirus vaccine derived from Sabin strain (“Sabin-IPV”).

Polio, or acute poliomyelitis, is a viral infectious disease which is commonly referred to as infantile paralysis due to its high prevalence among children. In Japan, although live polio vaccine derived from attenuated Sabin-strain poliovirus has been used in periodic regular immunization, vaccine-associated paralytic poliomyelitis (VAPP) is found to develop in one of several million vaccine recipients, an